159 Longitudinal tau PET and cognition REFERENCES 1. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Journal of Neuropathology & Experimental Neurology. 2012;71:362-81. 2. Tanner JA, Rabinovici GD. Relationship between tau and cognition in the evolution of Alzheimer’s disease: New insights from tau PET. Journal of Nuclear Medicine. 2021;62:612-3. 3. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551-67. 4. Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain. 2019;142:1723-35. 5. Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain. 2017;140:3286-300. 6. Hanseeuw BJ, Betensky RA, Jacobs HI, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA neurology. 2019;76:915-24. 7. Cho H, Choi JY, Lee HS, Lee JH, Ryu YH, Lee MS, et al. Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. Journal of Nuclear Medicine. 2019;60:1611-21. 8. Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA neurology. 2021;78:961-71. 9. Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature Medicine. 2022:1-7. 10. Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E, Ceyssens S, Van Broeckhoven C, et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: Validation against 15O-H2O PET. Alzheimer’s & Dementia. 2019;15:1172-82. 11. Peretti DE, Vállez García D, Reesink FE, Doorduin J, de Jong BM, De Deyn PP, et al. Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease. EJNMMI research. 2019;9:1-9. 12. Wolters E, Van de Beek M, Ossenkoppele R, Golla SS, Verfaillie S, Coomans E, et al. Tau PET and relative cerebral blood flow in dementia with Lewy bodies: a PET study. NeuroImage: Clinical. 2020;28:102504. 13. Leeuwis AE, Benedictus MR, Kuijer JP, Binnewijzend MA, Hooghiemstra AM, Verfaillie SC, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimer’s & Dementia. 2017;13:531-40. 6
RkJQdWJsaXNoZXIy MjY0ODMw